恩替卡韦联合吗替麦考酚酯治疗乙型肝炎病毒相关性肾炎疗效评价

摘要

Objective To investigate the clinical curative effect of entecavir combined with mycoPhenolate mofetil on hePatitis B virus associated glomerulonePhritis. Methods 58 cases of Patients diagnosed HBVGN were randomly divided in to the control grouP ( n=29 ) and the observation grouP ( n=29 ) ,the control grouP was given a grant for entecavir combined with Prednisolone acetate,the observation grouP received entecavir combined with mycoPhenolate mofetil. Results The total effective rate was 89. 65% in the observation grouP, which was significantly higher than 75. 86% in the control grouP ( P 0. 05 ) . 24 h urine Protein and serum creatinine were significantly decreased in the two grouPs after treatment,and the observation grouP was significantly lower than that in the control grouP ( P 0. 05 ) . There was no significant difference between the two grouPs in the incidence of adverse drug reactions ( P > 0. 05 ) . Conclusion The efficacy of Entecavir combined with mycoPhenolate mofetil in treating HBVGN is exact with good safety.%目的：探讨恩替卡韦联合吗替麦考酚酯治疗乙型肝炎病毒相关性肾炎（HBVGN）的临床疗效并评价其安全性。方法选择收治的HBVGN患者58例，随机分为对照组和观察组，各29例。对照组予恩替卡韦联合醋酸泼尼松龙，观察组予恩替卡韦联合吗替麦考酚酯。结果对照组患者治疗总有效率为89.65％，高于对照组的75.86％（ P ＜0.05）。两组患者 HBV－DNA水平较治疗前均明显下降（ P＜0.05），但组间未见显著性差异（ P＞0.05）。治疗后两组患者24 h尿蛋白及血肌酐较前均有明显下降，且观察组下降程度较对照组明显（ P＜0.05）。治疗后两组患者白蛋白较前明显上升，而丙氨酸氨基转移酶及天门冬酸氨基转移酶较前明显下降（ P＜0.05），而治疗后两组上述指标间未见明显差异（ P＞0.05）。两组患者药品不良反应发生率间未见明显差异（ P＞0.05）。结论恩替卡韦联合吗替麦考酚酯治疗HBVGN疗效确切，且安全性良好。